StockNews.AI
LGND
StockNews.AI
187 days

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

1. LGND will report Q4 and FY 2024 financial results on February 27, 2025. 2. A conference call will follow at 8:30 a.m. ET the same day. 3. Ligand emphasizes growth through partnerships and innovative technologies like Captisol®. 4. The company's model aims for diversified revenue streams from biopharmaceuticals. 5. Industry collaboration is a key strategy to enhance Ligand's market position.

Earnings
+6.41%Current Return
VS
+1.19%S&P 500
$111.3902/13 07:28 AM EDTEvent Start
$118.5302/14 02:02 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

The scheduled earnings report typically increases investor interest and stock activity. Past earnings calls have led to positive stock movements for LGND.

How important is it?

The forthcoming earnings report is crucial for assessing LGND's financial health and future strategy. Stakeholders often react significantly to financial disclosures, influencing stock valuation.

Why Short Term?

The financial results may drive immediate stock reactions before and after the call. Similar past events have resulted in short-term volatility in LGND's stock price.

Related Companies

AMGNMRKPFEGILDBAX
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2024 financial results before the opening of the U.S. financial markets on Thursday, February 27, 2025. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, February 27, 2025 Time: 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) Conference Call: (800) 715-9871 (U.S. & Canada) (646) 307-1963 (International) Conference ID is 8755336 Webcast: Live and replay webcasts of the call are available here. About Ligand Pharmaceuticals Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Its business model seeks to generate value for stockholders by creating a diversified portfolio of biopharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand’s goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Its business model focuses on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing its technology to help partners discover and develop medicines. Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate its revenue. Ligand’s Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand’s NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. Ligand has established multiple alliances, licenses and other business relationships with the world’s leading biopharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences, and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X @Ligand_LGND. We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.

Related News